The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.
Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.
Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.
Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen.
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
